Kezar Life Sciences (KZR) Competitors $7.49 +0.11 (+1.49%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrends KZR vs. NXTC, HOOK, GNFT, SOPH, ZNTL, SLN, INBX, ZURA, SLDB, and XBITShould you be buying Kezar Life Sciences stock or one of its competitors? The main competitors of Kezar Life Sciences include NextCure (NXTC), Hookipa Pharma (HOOK), Genfit (GNFT), SOPHiA GENETICS (SOPH), Zentalis Pharmaceuticals (ZNTL), Silence Therapeutics (SLN), Inhibrx (INBX), Zura Bio (ZURA), Solid Biosciences (SLDB), and XBiotech (XBIT). These companies are all part of the "medical" sector. Kezar Life Sciences vs. NextCure Hookipa Pharma Genfit SOPHiA GENETICS Zentalis Pharmaceuticals Silence Therapeutics Inhibrx Zura Bio Solid Biosciences XBiotech Kezar Life Sciences (NASDAQ:KZR) and NextCure (NASDAQ:NXTC) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, community ranking, analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment and earnings. Do institutionals & insiders have more ownership in KZR or NXTC? 67.9% of Kezar Life Sciences shares are held by institutional investors. Comparatively, 42.7% of NextCure shares are held by institutional investors. 9.3% of Kezar Life Sciences shares are held by company insiders. Comparatively, 13.3% of NextCure shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the media refer more to KZR or NXTC? In the previous week, Kezar Life Sciences had 8 more articles in the media than NextCure. MarketBeat recorded 9 mentions for Kezar Life Sciences and 1 mentions for NextCure. Kezar Life Sciences' average media sentiment score of 0.46 beat NextCure's score of 0.00 indicating that Kezar Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kezar Life Sciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral NextCure 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate KZR or NXTC? Kezar Life Sciences presently has a consensus price target of $40.50, suggesting a potential upside of 440.72%. NextCure has a consensus price target of $4.00, suggesting a potential upside of 207.69%. Given Kezar Life Sciences' higher probable upside, equities research analysts clearly believe Kezar Life Sciences is more favorable than NextCure.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kezar Life Sciences 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00NextCure 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community prefer KZR or NXTC? Kezar Life Sciences received 56 more outperform votes than NextCure when rated by MarketBeat users. However, 64.52% of users gave NextCure an outperform vote while only 57.38% of users gave Kezar Life Sciences an outperform vote. CompanyUnderperformOutperformKezar Life SciencesOutperform Votes13657.38% Underperform Votes10142.62% NextCureOutperform Votes8064.52% Underperform Votes4435.48% Which has stronger valuation & earnings, KZR or NXTC? NextCure has lower revenue, but higher earnings than Kezar Life Sciences. NextCure is trading at a lower price-to-earnings ratio than Kezar Life Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKezar Life Sciences$7M7.81-$101.87M-$13.18-0.57NextCureN/AN/A-$62.72M-$2.09-0.62 Which has more volatility & risk, KZR or NXTC? Kezar Life Sciences has a beta of 0.22, suggesting that its share price is 78% less volatile than the S&P 500. Comparatively, NextCure has a beta of 0.8, suggesting that its share price is 20% less volatile than the S&P 500. Is KZR or NXTC more profitable? Kezar Life Sciences' return on equity of -54.95% beat NextCure's return on equity.Company Net Margins Return on Equity Return on Assets Kezar Life SciencesN/A -54.95% -46.11% NextCure N/A -62.50%-53.67% SummaryKezar Life Sciences beats NextCure on 9 of the 16 factors compared between the two stocks. Ad DTIDownload Our Tesla Ebook For FreeLike many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.To claim your copy free of charge simply follow this link. Get Kezar Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for KZR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KZR vs. The Competition Export to ExcelMetricKezar Life SciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$54.68M$6.44B$5.06B$8.82BDividend YieldN/A8.11%5.18%4.07%P/E Ratio-0.5710.78126.3217.81Price / Sales7.81243.711,179.2574.56Price / CashN/A22.1633.8632.53Price / Book0.295.474.684.68Net Income-$101.87M$153.61M$119.54M$226.08M7 Day Performance-0.40%-2.00%-1.83%-1.04%1 Month Performance-5.47%-7.46%-3.60%1.04%1 Year Performance-14.89%31.82%31.91%26.28% Kezar Life Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KZRKezar Life Sciences4.3591 of 5 stars$7.49+1.5%$40.50+440.7%-15.4%$53.85M$7M-0.5760Analyst RevisionNXTCNextCure4.3842 of 5 stars$1.30-0.8%$4.00+207.7%+4.8%$36.69MN/A0.0090HOOKHookipa Pharma2.4727 of 5 stars$2.72-2.5%$44.00+1,517.6%-46.4%$33.63M$20.13M0.0056GNFTGenfit1.4555 of 5 stars$4.31+1.2%$13.00+201.6%+27.1%$215.28M$41.31M0.00120SOPHSOPHiA GENETICS1.4237 of 5 stars$3.17-3.1%$6.50+105.0%-14.6%$213.78M$62.37M0.00520ZNTLZentalis Pharmaceuticals2.5838 of 5 stars$3.13+4.7%$10.00+219.5%-71.1%$213.08MN/A0.00160Analyst RevisionSLNSilence Therapeutics3.6458 of 5 stars$6.93-0.6%$57.20+725.4%-27.1%$208.60M$31.55M0.00100Analyst ForecastNews CoverageHigh Trading VolumeINBXInhibrx1.2884 of 5 stars$14.04-1.7%N/A-36.9%$206.86M$1.63M0.00166ZURAZura Bio3.9024 of 5 stars$2.90-7.9%$15.80+444.8%-35.1%$205.68MN/A0.003Analyst ForecastSLDBSolid Biosciences3.6066 of 5 stars$4.96-2.9%$15.14+205.3%+108.4%$204.17M$8.09M0.00100XBITXBiotech0.8929 of 5 stars$6.49-2.7%N/A+77.8%$203.32M$4.01M0.00100Positive News Related Companies and Tools Related Companies NXTC Competitors HOOK Competitors GNFT Competitors SOPH Competitors ZNTL Competitors SLN Competitors INBX Competitors ZURA Competitors SLDB Competitors XBIT Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:KZR) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kezar Life Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kezar Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KZR Stock Alerts